Back to Search Start Over

Serum anandamide and lipids associated with linoleic acid can distinguish interstitial cystitis/bladder pain syndrome from overactive bladder: An exploratory study.

Authors :
Torimoto, Kazumasa
Ueda, Tomohiro
Gotoh, Daisuke
Kano, Kuniyuki
Miyake, Makito
Nakai, Yasushi
Hori, Shunta
Morizawa, Yosuke
Onishi, Kenta
Shimizu, Takuto
Tomizawa, Mitsuru
Aoki, Junken
Fujimoto, Kiyohide
Source :
LUTS; Nov2023, Vol. 15 Issue 6, p238-246, 9p
Publication Year :
2023

Abstract

Objectives: Diagnosing interstitial cystitis/bladder pain syndrome presents a major challenge because it relies on subjective symptoms and empirical cystoscopic findings. A practical biomarker should discriminate diseases that cause increased urinary frequency, particularly overactive bladder. Therefore, we aimed to identify blood biomarkers that can discriminate between interstitial cystitis/bladder pain syndrome and overactive bladder. Methods: We enrolled patients with Hunner‐type interstitial cystitis (n = 20), bladder pain syndrome (n = 20), and overactive bladder (n = 20) and without lower urinary tract symptoms (controls, n = 15) at Ueda Clinic and Nara Medical University Hospital from February 2020 to August 2021. The degree of interstitial cystitis/bladder pain syndrome symptoms was evaluated using the interstitial cystitis symptom and problem indices. Metabolomics analysis was performed on 323 serum metabolites using liquid chromatography time‐of‐flight mass spectrometry. Results: In the Hunner‐type interstitial cystitis or bladder pain syndrome group, we observed smaller relative areas, including anandamide, acylcarnitine (18:2), linoleoyl ethanolamide, and arachidonic acid, compared to those in the overactive bladder or control group. Notably, the differences in the relative areas of anandamide were statistically significant (median: 3.950e‐005 and 4.150e‐005 vs. 8.300e‐005 and 9.800e‐005), with an area under the curve of 0.9321, demonstrating its ability to discriminate interstitial cystitis/bladder pain syndrome. Conclusions: Serum anandamide may be a feasible diagnostic biomarker for interstitial cystitis/bladder pain syndrome. Reduced serum anandamide levels may be associated with pain and inflammation initiation, reflecting the pathology of interstitial cystitis/bladder pain syndrome. Furthermore, our findings suggest that abnormal linoleic acid metabolism may be involved in the pathogenesis of interstitial cystitis/bladder pain syndrome. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17575664
Volume :
15
Issue :
6
Database :
Complementary Index
Journal :
LUTS
Publication Type :
Academic Journal
Accession number :
173396984
Full Text :
https://doi.org/10.1111/luts.12501